CARMAT voluntarily suspends Aeson implantations on a temporary basis

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure,announces that it has voluntarilysuspended, on a temporary basis, theimplants of its Aeson® artificial heart.

Following  the  occurrence  of  a qualityissueaffecting  some  of  its  prostheses,  the  Company  has  decided  to temporarily suspend, as a precautionary measure, implantsof its Aeson® artificial heart.

This  event  will  be  investigated  in  accordance  with  the  protocol  planned  for  this  purpose.  Following  this investigation, CARMAT will communicate,as soon as it is able to do so, on the resumption of its implants